Abstract
The International Classification of Sleep Disorders (ICSD-3) produced by the American Academy of Sleep Medicine is a major revision of the prior classification and was published in 2014. It is a major advance over previous versions but it is unfortunate that some of the diagnostic criteria differ from that of the American Psychiatric Association’s revised version of the Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-V) published in 2013 which includes a smaller section entitled “Sleep Wake Disorders.” The DSM-V serves as an entry level classification, mainly for psychiatrists, and it is to be hoped that in the future the two classifications will be merged into one that will cause less confusion not only for clinicians but also for agencies that reimburse for health care and provide for treatment options. This review discusses the main features of the diagnostic entries in the ICSD-3 and presents the pharmacological treatment focus for the disorders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmed I, Thorpy M (2010) Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med 31(2):371–381
American Academy of Sleep Medicine (2014) International classification of sleep disorders, 3rd edn. American Academy of Sleep Medicine, Darien, IL
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5 DSM-Vth edn. American Psychiatric Association, Washington, DC
Andlauer O, Moore H, Jouhier L et al (2013) Nocturnal REM sleep latency for identifying patients with narcolepsy/hypocretin deficiency. JAMA Neurol 6:1–12
Arnulf I, Lin L, Gadoth N et al (2008) Kleine-Levin syndrome: a systematic study of 108 patients. Ann Neurol 63:482–493
Attarian H, Zhu L (2013) Treatment options for disorders of arousal: a case series. Int J Neurosci 123(9):623–625
Bertisch SM, Herzig SJ, Winkelman JW, Buettner C (2014) National use of prescription medications for insomnia: NHANES 1999–2010. Sleep 37(2):343–349
Brunetti V, Losurdo A, Testani E et al (2014) Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. Curr Alzheimer Res 11(3):267–273
Chisholm T, Morehouse RL (1996) Adult headbanging: sleep studies and treatment. Sleep 19(4):343–346
Dhillon S, Clarke M (2014) Tasimelteon: first global approval. Drugs 74(4):505–511
Edinger JD, Wyatt JK, Stepanski EJ et al (2011) Testing the reliability and validity of DSM-IV-TR and ICSD-2 insomnia diagnoses: results of a multi-method/multi-trait analysis. Arch Gen Psychiatry 68:992–1002
Hudgel DW (1995) Pharmacologic treatment of obstructive sleep apnea. J Lab Clin Med 126(1):13–18
International Classification of Diseases (2010) Tenth Revision, Clinical Modification (ICD-10-CM), National Center for Health Statistics. Centers for Disease Control and Prevention (CDC), December 20, 2010
Lavault S, Dauvilliers Y, Drouot X et al (2011) Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Med 12(6):550–556
Mahdavi-Zafarghandi R, Seyedi A (2014) Treatment of monosymptomatic nocturnal enuresis: sertraline for non-responders to desmopressin. Iran J Med Sci 39(2):136–139
McCarter SJ, Boswell CL, St Louis EK et al (2013) Treatment outcomes in REM sleep behavior disorder. Sleep Med 14(3):237–242
Morgenthaler TI, Lee-Chiong T, Alessi C et al (2007) Standards of practice committee of the American academy of sleep medicine. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American academy of sleep medicine report. Sleep 30(11):1445–1459
Nittur N, Konofal E, Dauvilliers Y et al (2013) Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med 14(1):30–36
Palikh GM, Vaughn BV (2010) Topiramate responsive exploding head syndrome. J Clin Sleep Med 6(4):382–383
Schenck CH, Howell MJ (2013) Spectrum of RBD (overlap between RBD and other parasomnias). Sleep Biol Rhythms 11(Suppl 1):27–34
Schwartz TL, Goradia V (2013) Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon. Drugs Context 2013:212257. doi:10.7573/dic.212257
Silber MH, Becker PM, Earley C et al (2013) Medical advisory board of the Willis-Ekbom disease foundation. Willis-Ekbom disease foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc 88(9):977–986
Thorpy MJ, Roth T (2013) Toward a classification of medications for sleep and circadian rhythm disorders. Nat Sci Sleep 5:143–145
Touitou Y, Bogdan A (2007) Promoting adjustment of the sleep-wake cycle by chronobiotics. Physiol Behav 90(2–3):294–300
Westhoff M, Arzt M, Litterst P (2012) Prevalence and treatment of central sleep apnoea emerging after initiation of continuous positive airway pressure in patients with obstructive sleep apnoea without evidence of heart failure. Sleep Breath 16:71–78
Zisapel N (2012) Drugs for insomnia. Expert Opin Emerg Drugs 17(3):299–317
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Thorpy, M. (2015). Classification of Sleep Disorders. In: Guglietta, A. (eds) Drug Treatment of Sleep Disorders. Milestones in Drug Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-11514-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-11514-6_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-11513-9
Online ISBN: 978-3-319-11514-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)